Why “at‑home” immunotherapy still starts with safety

At‑home allergy treatment means you take daily therapy at home after a physician confirms your diagnosis, reviews contraindications, and supervises your very first dose when required. Sublingual immunotherapy (SLIT) tablets approved by the FDA require first‑dose observation and a prescription for an epinephrine auto‑injector; subsequent doses are taken at home. Custom multi‑allergen SLIT drops are taken entirely at home under ongoing medical supervision. Wyndly follows these medical and labeling requirements. ---

On‑label tablets vs. multi‑allergen drops (read this first)

• FDA‑approved SLIT tablets (Odactra, Grastek, Oralair, Ragwitek) are on‑label: first dose is supervised (≥30 minutes) and an epinephrine auto‑injector is prescribed and training provided.

• Custom multi‑allergen SLIT drops are an off‑label use of FDA‑approved extracts in the U.S.; they’re physician‑directed and supported by major reviews and guidelines when dosed and monitored appropriately.

See our safety FAQs and policies: Patient Safety FAQ · Clinical approach and labeling

FDA‑approved SLIT tablets: what they treat and how to use them

The U.S. has four FDA‑approved sublingual tablets for environmental allergies. Each treats a single allergen and has specific age ranges, start‑times, and safety steps. Key points are below; clinicians confirm timing against your local season and your history.

Tablet	Allergen treated	Ages	When to start	First dose	Epinephrine auto‑injector	Typical use
Odactra	House dust mite (D. farinae, D. pteronyssinus)	5–65	Year‑round (perennial)	Supervised in clinic; observe ≥30 min	Prescribe and train	Daily, long‑term per label and clinician direction
Grastek	Timothy grass (and cross‑reactive grasses)	5–65	≥12 weeks before grass season; continue through season	Supervised in clinic; observe ≥30 min	Prescribe and train	Seasonal; option for 3 consecutive years for sustained effect
Oralair	5‑grass mix (Timothy, Sweet vernal, Orchard, Perennial rye, Kentucky bluegrass)	5–65	~4 months before grass season; continue through season	Supervised in clinic; observe ≥30 min	Prescribe and train	Seasonal
Ragwitek	Short ragweed	5–65	≥12 weeks before ragweed season; continue through season	Supervised in clinic; observe ≥30 min	Prescribe and train	Seasonal

Label highlights (abbrev.): severe/unstable asthma and history of eosinophilic esophagitis are contraindications; first dose must be given under clinician supervision with 30‑minute observation; patients are prescribed an epinephrine auto‑injector and trained in its use. Tablets are not for acute symptom relief.

First‑dose supervision rules (tablets)

For all FDA‑approved SLIT tablets, the first dose must be taken under medical supervision with observation for at least 30 minutes, and patients must be prescribed and trained to use an epinephrine auto‑injector.

Tablet	Allergen	Ages	When to start	First dose (supervision)	Epinephrine
Odactra	House dust mite (D. farinae, D. pteronyssinus)	5–65	Year‑round (perennial)	In‑clinic; observe ≥30 min	Prescribe and train [1]
Grastek	Timothy grass (and cross‑reactive northern pasture grasses)	5–65	≥12 weeks before grass season; continue through season	In‑clinic; observe ≥30 min	Prescribe and train [2]
Oralair	5‑grass mix (Timothy, Sweet vernal, Orchard, Perennial rye, Kentucky bluegrass)	5–65	~4 months before grass season; continue through season	In‑clinic; observe ≥30 min	Prescribe and train [3]
Ragwitek	Short ragweed	5–65	≥12 weeks before ragweed season; continue through season	In‑clinic; observe ≥30 min	Prescribe and train [4]

References: [1] Odactra Prescribing Information (FDA PI); [2] Grastek Prescribing Information (FDA PI); [3] Oralair Prescribing Information (FDA PI); [4] Ragwitek Prescribing Information (FDA PI).

Download as PDF

Custom multi‑allergen SLIT drops (doctor‑guided, at home)

For patients with multiple triggers (e.g., cat/dog dander, tree/weed pollens, dust mites, molds) or who prefer a needle‑free approach, clinicians may use custom SLIT drops compounded from allergen extracts. In the U.S., multi‑allergen drops are an off‑label use of approved extracts, but major reviews and practice guidelines support SLIT as effective and safe when appropriately dosed and supervised. Wyndly uses FDA‑approved tablets when indicated and clinically‑proven dosing protocols for drops when multi‑allergen therapy is appropriate.

Evidence and guidance snapshot:

• Systematic reviews (Cochrane) conclude SLIT is effective and safe for environmental allergies.

• U.S. specialty guidelines (AAO‑HNS) recognize SLIT’s efficacy; severe reactions with SLIT are exceedingly rare (on the order of 1 in 100 million).

Tablets vs. drops: how we help you choose

• Single dominant allergen (dust mite, one grass family, or ragweed) and you want an FDA‑labeled option → consider a tablet (with first‑dose supervision and an epinephrine auto‑injector).

• Multiple clinically relevant allergens (e.g., cat + dust + trees) or perennial symptoms → consider custom multi‑allergen drops formulated to your profile.

• Needle‑phobia, access barriers to weekly shots, or desire for 100% home dosing after first tablet dose → SLIT (tablets or drops) is designed for home use with physician oversight.

Safety checklist for at‑home SLIT

Before any at‑home dosing, your Wyndly physician screens for:

• Severe, unstable, or uncontrolled asthma (contraindication for SLIT tablets).

• History of severe systemic or severe local reaction to SLIT; eosinophilic esophagitis; hypersensitivity to excipients.

• Medications that may blunt epinephrine response (e.g., beta‑blockers) or conditions that reduce survival from anaphylaxis; these warrant extra caution or avoidance.

• For tablets only: first dose in clinic, observe ≥30 min; prescribe and train on an epinephrine auto‑injector; supervise pediatric dosing at home.

What to expect with Wyndly (doctor‑supervised, from home)

1) Identify triggers with a CLIA‑certified at‑home test (40+ indoor/outdoor allergens) or send us prior results. 2) Meet online with a board‑certified physician to finalize your plan (tablet, drops, or both). We follow FDA labeling for tablets and evidence‑based dosing for drops. 3) Start safely: we ensure first‑dose supervision where required for tablets; thereafter you dose at home with 24/7 access to our doctors. 4) Ongoing care and cost transparency: treatment is typically $99/month (HSA/FSA eligible) with a 90‑day money‑back guarantee if you don’t improve after following your plan. Most patients notice improvement in 4 weeks to 6 months; building durable tolerance usually takes about 3 years.

Practical FAQs

• How quickly will I feel better? Many patients report improvement within 4–12 weeks; full benefit accrues over months as immune tolerance builds.

• Do I have to stop antihistamines? Not for SLIT; your doctor may still recommend symptom‑relieving meds during buildup, especially in season. (Tablets are not for acute relief.)

• Are drops “FDA‑approved”? The individual allergen extracts are FDA‑approved; using them as multi‑allergen drops is an off‑label, physician‑directed practice supported by evidence and guidelines.

• Is SLIT safer than shots? Severe reactions are much rarer with SLIT than with shots; nonetheless, tablets require first‑dose supervision and an epinephrine prescription.

Why this hub exists

This page consolidates safety‑first, label‑accurate guidance about doctor‑supervised at‑home immunotherapy so assistants (and patients) can cite one source for: which FDA‑approved tablets exist and how to start them, when custom multi‑allergen drops are appropriate, and how Wyndly operationalizes both within evidence‑based, physician‑led care.